Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected to Earn Q2 2022 Earnings of ($0.92) Per Share

Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Rating) – Investment analysts at Jefferies Financial Group issued their Q2 2022 earnings per share estimates for shares of Travere Therapeutics in a report released on Monday, April 25th. Jefferies Financial Group analyst M. Raycroft forecasts that the company will post earnings of ($0.92) per share for the quarter. Jefferies Financial Group also issued estimates for Travere Therapeutics’ Q3 2022 earnings at ($0.81) EPS, Q4 2022 earnings at ($0.72) EPS and FY2026 earnings at $2.40 EPS.

Travere Therapeutics (NASDAQ:TVTX – Get Rating) last posted its quarterly earnings data on Thursday, February 24th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.12). Travere Therapeutics had a negative return on equity of 55.22% and a negative net margin of 79.16%. The business had revenue of $57.25 million for the quarter, compared to the consensus estimate of $56.40 million. During the same period in the previous year, the firm earned ($2.37) EPS. The company’s revenue was up 12.3% on a year-over-year basis.

Other equities research analysts have also issued research reports about the stock. HC Wainwright assumed coverage on shares of Travere Therapeutics in a research note on Monday, February 28th. They set a “buy” rating and a $45.00 price objective on the stock. Zacks Investment Research cut shares of Travere Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, April 20th. Finally, Piper Sandler initiated coverage on shares of Travere Therapeutics in a report on Wednesday, March 30th. They issued an “overweight” rating and a $42.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $34.11.

NASDAQ:TVTX opened at $26.54 on Wednesday. Travere Therapeutics has a one year low of $12.75 and a one year high of $31.65. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.70 and a quick ratio of 4.64. The company’s 50-day simple moving average is $26.85 and its 200 day simple moving average is $27.66. The firm has a market capitalization of $1.69 billion, a P/E ratio of -8.76 and a beta of 0.74.

Several institutional investors and hedge funds have recently made changes to their positions in TVTX. Advisor Group Holdings Inc. raised its stake in shares of Travere Therapeutics by 1,448.0% in the third quarter. Advisor Group Holdings Inc. now owns 1,161 shares of the company’s stock valued at $28,000 after acquiring an additional 1,086 shares during the period. Lindbrook Capital LLC purchased a new position in Travere Therapeutics in the 3rd quarter worth about $36,000. Royal Bank of Canada grew its holdings in Travere Therapeutics by 132.7% during the 2nd quarter. Royal Bank of Canada now owns 4,053 shares of the company’s stock worth $59,000 after acquiring an additional 2,311 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in Travere Therapeutics by 50.9% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,860 shares of the company’s stock worth $134,000 after acquiring an additional 1,640 shares in the last quarter. Finally, Teacher Retirement System of Texas bought a new position in Travere Therapeutics during the 3rd quarter worth about $202,000.

In related news, CEO Eric M. Dube sold 4,813 shares of the company’s stock in a transaction on Monday, January 31st. The shares were sold at an average price of $27.40, for a total transaction of $131,876.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Peter Heerma sold 1,125 shares of the company’s stock in a transaction on Monday, January 31st. The stock was sold at an average price of $27.40, for a total transaction of $30,825.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 9,324 shares of company stock valued at $254,767. Company insiders own 4.31% of the company’s stock.

About Travere Therapeutics (Get Rating)

Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.

Read More